• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center



Myeloma SPORE

The DF/HCC SPORE in multiple myeloma (Myeloma SPORE) is a key component of the DF/HCC program to find new treatments for multiple myeloma. This cancer of the blood-forming tissues affects 14,000 new individuals in the United States each year, with 50,000 total patients, and remains incurable despite conventional and high-dose therapies. Among the six collaborative projects underway is an effort to identify the genes involved and develop appropriate target drugs to prevent or delay disease progression.

Myeloma SPORE Principal Investigator: Kenneth Anderson, MD (DFCI)